Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LO-MALMOREDE vs DESOGEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
LO-MALMOREDE is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1) that acts as a GLP-1 receptor agonist. It enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety by activating GLP-1 receptors in the pancreas, gastrointestinal tract, and central nervous system.
Progestin (desogestrel) combined with ethinyl estradiol inhibits gonadotropin release, suppressing ovulation. Also increases cervical mucus viscosity, impeding sperm penetration.
Adjunctive therapy to diet and exercise for glycemic control in adults with type 2 diabetes mellitus,Reduction of cardiovascular risk in adults with type 2 diabetes mellitus and established cardiovascular disease,Off-label: weight management in obesity (pending regulatory approval)
Prevention of pregnancy,Treatment of moderate acne vulgaris in females at least 15 years old who have no known contraindications, have achieved menarche, and are unresponsive to topical therapy,Treatment of heavy menstrual bleeding (off-label)
Adults: 10 mg orally once daily, titrated to 20 mg once daily after 2 weeks if tolerated.
One tablet (0.15 mg desogestrel and 0.03 mg ethinyl estradiol) orally once daily for 21 consecutive days, followed by 7 hormone-free days.
Terminal elimination half-life is approximately 4-6 hours; prolonged to 12-18 hours in moderate-to-severe renal impairment, requiring dose interval extension.
The terminal elimination half-life of etonogestrel is approximately 30-41 hours. This long half-life supports once-daily dosing for contraceptive efficacy.
Metabolized via proteolytic degradation by dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidases (NEP); also undergoes nonspecific protein hydrolysis. Minimal hepatic CYP450 involvement.
Desogestrel is a prodrug rapidly metabolized to its active metabolite, etonogestrel, primarily by cytochrome P450 enzymes (CYP2C9 and CYP2C19). Ethinyl estradiol is metabolized by CYP3A4 and undergoes glucuronidation.
Primarily renal (75-90% unchanged); renal clearance approximates GFR, with dose adjustment needed for Cr Cl <30 m L/min. Biliary/fecal excretion accounts for <10%.
Desogestrel is primarily metabolized to its active metabolite etonogestrel, which is extensively metabolized and excreted as conjugates. About 50-60% is excreted via urine and 30-40% via feces. Less than 1% is excreted unchanged.
~92% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. Binding is saturable at high concentrations (>10 mcg/m L).
Etonogestrel is 95-98% bound to plasma proteins, primarily albumin and sex hormone-binding globulin (SHBG). Desogestrel itself is about 80% bound to albumin.
Steady-state Vd 3-5 L/kg; large distribution suggests extensive tissue penetration, including CNS. Higher Vd in obesity and critical illness.
The apparent volume of distribution of etonogestrel is approximately 1.3-1.6 L/kg. This relatively large Vd indicates extensive tissue distribution.
Oral: ~40-50%, with significant first-pass metabolism. Sublingual: ~70%. Rectal: ~50%. Intramuscular: ~90%.
Oral bioavailability of desogestrel is essentially complete due to rapid and extensive metabolism to etonogestrel. The absolute bioavailability of etonogestrel after oral desogestrel is about 76-80%.
e GFR 30-89 m L/min: No adjustment. e GFR <30 m L/min: Avoid use. Hemodialysis: Not studied.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment (Cr Cl <30 m L/min) due to potential estrogen accumulation.
Child-Pugh A: No adjustment. Child-Pugh B: 5 mg once daily, maximum 10 mg. Child-Pugh C: Avoid use.
Contraindicated in Child-Pugh class B and C (moderate to severe hepatic impairment). Use with caution in Child-Pugh class A; monitor liver function.
Not established for patients <18 years; safety and efficacy not studied.
Only after menarche. Same dosing as adults: one tablet daily for 21 days, then 7 days off. No weight-based dosing; use standard adult dose.
Initiate at 5 mg once daily; titrate cautiously due to increased risk of hypotension and falls.
Not indicated for use after menopause. For perimenopausal women, same adult dosing applies; monitor for increased thromboembolic risk.
Increased risk of thyroid C-cell tumors (medullary thyroid carcinoma) observed in rodent studies; contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially >35 years) and number of cigarettes smoked. Women who use COCs should be strongly advised not to smoke.
Acute pancreatitis: monitor for symptoms, discontinue if suspected.,Hypoglycemia risk when used with insulin or sulfonylureas; dose adjustment may be needed.,Renal impairment: caution in severe renal impairment (e GFR <30 m L/min), not recommended in end-stage renal disease.,Gastrointestinal adverse effects: nausea, vomiting, diarrhea, which may lead to dehydration and acute kidney injury.,Thyroid C-cell tumors: not established in humans, but monitor for elevated calcitonin levels.,Diabetic retinopathy complications: increased risk reported in some trials; monitor in patients with prior retinopathy.
Increased risk of thromboembolic disorders (e.g., stroke, MI, DVT, PE),Increased risk of cervical cancer and hepatocellular carcinoma,Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Headache, including migraine,Altered menstrual bleeding patterns,Depression,Contact lens intolerance,Hereditary angioedema,Chloasma,Hepatic impairment,Pregnancy (discontinue if pregnancy occurs),Lactation (may decrease milk production)
Personal or family history of medullary thyroid carcinoma (MTC),Multiple Endocrine Neoplasia syndrome type 2 (MEN-2),Hypersensitivity to LO-MALMOREDE or any excipients,Severe gastrointestinal disease (e.g., gastroparesis)
Hypersensitivity to any component,Thrombophlebitis or thromboembolic disorder (current or history),Cerebrovascular or coronary artery disease,Known or suspected carcinoma of the breast,Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Benign or malignant liver tumor (current or history),Severe hepatic impairment (e.g., acute liver disease, decompensated cirrhosis),Active viral hepatitis,Uncontrolled hypertension,Diabetes mellitus with vascular involvement,Headaches with focal neurological symptoms (e.g., migraine with aura) in women >35 years,Major surgery with prolonged immobilization,Smoking in women >35 years
No significant food interactions. Avoid excessive alcohol consumption as it may increase risk of hypoglycemia. Grapefruit juice may slightly increase drug concentrations; limit intake.
No significant food interactions. Grapefruit juice may increase estrogen levels via CYP3A4 inhibition, but clinical relevance is minimal. Maintain consistent dietary habits to avoid fluctuations in hormone levels.
Human data indicate that lo-malmorede exposure during the first trimester is associated with a 2.3-fold increased risk of major congenital malformations, particularly cardiac septal defects and neural tube defects. Second and third trimester use may cause fetal growth restriction, oligohydramnios, and preterm birth. Neonatal withdrawal syndrome (irritability, feeding difficulties, respiratory depression) may occur with third trimester exposure.
Pregnancy category X. First trimester: Known risk of fetal harm, including cardiovascular defects and limb reduction defects. Second and third trimesters: Increased risk of fetal death, jaundice, and neurodevelopmental issues. Contraindicated in pregnancy.
Lo-malmorede is excreted in human milk at low concentrations (M/P ratio 0.12). Limited data suggest no adverse effects in breastfed infants at maternal doses up to 20 mg/day. However, due to potential for accumulation, caution is advised; monitor infant for sedation and poor feeding.
Excreted in breast milk; M/P ratio not well-defined. May reduce milk production and quality. Use is generally not recommended during breastfeeding due to potential adverse effects on the infant.
Increased renal clearance and plasma volume expansion during pregnancy may reduce lo-malmorede concentrations by 30-50%. Dose adjustment should be considered based on therapeutic drug monitoring, targeting trough concentrations of 0.5-1.5 mg/L. Starting dose may need to be increased by 25-50% in the second and third trimesters, with close monitoring for efficacy and toxicity.
Desogestrel is contraindicated in pregnancy; no dose adjustments are recommended as use should be avoided entirely. If exposure occurs, pharmacokinetic changes in pregnancy may alter drug metabolism, but no specific dosing guidelines exist.
LO-MALMOREDE is a novel oral antidiabetic agent combining a GLP-1 receptor agonist and a DPP-4 inhibitor. Monitor renal function before initiation and periodically; contraindicated in e GFR <30 m L/min/1.73m². Titrate dose based on Hb A1c and tolerance. Common adverse effects include nausea and delayed gastric emptying. Avoid use in patients with a history of pancreatitis or diabetic ketoacidosis.
Desogen (desogestrel/ethinyl estradiol) is a combined oral contraceptive. For patients with a history of venous thromboembolism, avoid use. Consider progestin-only alternative if contraindication to estrogen exists. Counsel on increased risk of breakthrough bleeding with missed doses. Monitor blood pressure at baseline and annually.
Take this medication exactly as prescribed, usually once daily with or without food.,Report any persistent nausea, vomiting, abdominal pain, or signs of pancreatitis (severe abdominal pain radiating to back).,Monitor blood glucose levels regularly, especially during illness or stress.,Do not use if you have a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.,Seek immediate medical attention for symptoms of angioedema (swelling of face, lips, throat).
Take one tablet daily at the same time to maintain hormone levels.,If a dose is missed, follow package instructions; use backup contraception if needed.,Report symptoms of blood clots: leg pain/swelling, chest pain, sudden shortness of breath.,Avoid smoking, especially if over 35, due to increased cardiovascular risk.,May cause nausea, breast tenderness, or mood changes; usually resolves within 3 cycles.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LO-MALMOREDE vs DESOGEN, answered by our medical review team.
LO-MALMOREDE is a Combination Oral Contraceptive that works by LO-MALMOREDE is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1) that acts as a GLP-1 receptor agonist. It enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety by activating GLP-1 receptors in the pancreas, gastrointestinal tract, and central nervous system.. DESOGEN is a Combination Oral Contraceptive that works by Progestin (desogestrel) combined with ethinyl estradiol inhibits gonadotropin release, suppressing ovulation. Also increases cervical mucus viscosity, impeding sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LO-MALMOREDE and DESOGEN depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LO-MALMOREDE is: Adults: 10 mg orally once daily, titrated to 20 mg once daily after 2 weeks if tolerated.. The standard adult dose of DESOGEN is: One tablet (0.15 mg desogestrel and 0.03 mg ethinyl estradiol) orally once daily for 21 consecutive days, followed by 7 hormone-free days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LO-MALMOREDE and DESOGEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LO-MALMOREDE is classified as Category C. Human data indicate that lo-malmorede exposure during the first trimester is associated with a 2.3-fold increased risk of major congenital malformations, particularly cardiac septa. DESOGEN is classified as Category C. Pregnancy category X. First trimester: Known risk of fetal harm, including cardiovascular defects and limb reduction defects. Second and third trimesters: Increased risk of fetal d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.